

Datasheet: PHP105

Description:	RECOMBINANT HUMAN FGF BASIC
Name:	FGF BASIC
Other names:	FGF2
Format:	Rec. Protein
Product Type:	Recombinant Protein
Quantity:	50 µg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			0.2 - 0.4 ng/well
Western Blotting	▪			1.5 - 3.0 ng/lane
Functional Assays	▪			0.1 - 10 ng/ml

Where this protein has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the protein for use in their own system using appropriate negative/positive controls.

Target Species	Human
Product Form	Purified recombinant protein expressed in <i>E. coli</i> - lyophilized
Reconstitution	Reconstitute with 0.5 ml Tris (5mM, pH7.6). Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. Further dilutions may be prepared in a buffer containing a carrier protein (eg 0.1% BSA).
Buffer Solution	TRIS buffered saline.
Preservative Stabilisers	None present
Carrier Free	Yes
Endotoxin Level	< 0.1 ng/ug
Approx. Protein Concentrations	Total protein concentration 0.1 mg/ml after reconstitution.
External Database Links	UniProt: P09038 Related reagents

Entrez Gene:[2247](#) FGF2 [Related reagents](#)**Synonyms**

FGFB

Product Information

Recombinant Human FGF basic represents the C-terminal portion of human fibroblast growth factor 2 (A¹³⁵ - S²⁸⁸).

Fibroblast growth factor basic (FGF basic), also known as FGF 2, is a heparin binding growth factor which has stimulatory activity on a range of cells of mesenchymal, neuroectodermal and endothelial origin.

Note: FGF basic is sensitive to acidic conditions.

Protein Molecular Weight

17.2 kD (154 amino acid sequence)

Activity2 x 10⁶ units/mg**Purity**

>95% by SDS PAGE and HPLC analysis

ELISA

This product may be used as a standard for ELISA applications with either [AHP1038](#) or [AHP1038B](#).

Western Blotting

This product may be used as the positive control for Western Blot applications with either [AHP1038](#) or [AHP1038B](#).

References

1. Svendsen, C.N. *et al.* (1997) Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. [Exp Neurol. 148: 135-46.](#)
2. Kim, T.H. *et al.* (2005) Recombinant human prothrombin kringle-2 induces bovine capillary endothelial cell cycle arrest at G0-G1 phase through inhibition of cyclin D1/CDK4 complex: modulation of reactive oxygen species generation and up-regulation of cyclin-dependent kinase inhibitors. [Angiogenesis. 8: 307-14.](#)
3. van Beuningen, HM *et al.* (2014) Inhibition of TAK1 and/or JAK can rescue impaired chondrogenic differentiation of human mesenchymal stem cells in osteoarthritis-like conditions. [Tissue Eng Part A. 20 \(15-16\): 2243-52.](#)
4. Pleumeekers, M.M. *et al.* (2014) The *in vitro* and *in vivo* capacity of culture-expanded human cells from several sources encapsulated in alginate to form cartilage. [Eur Cell Mater. 27: 264-80.](#)
5. Willems, N. *et al.* (2015) Intradiscal application of rhBMP-7 does not induce regeneration in a canine model of spontaneous intervertebral disc degeneration. [Arthritis Res Ther. 17: 137.](#)
6. Pleumeekers, M.M. *et al.* (2015) Cartilage regeneration in the head and neck area: Combination of ear or nasal chondrocytes and mesenchymal stem cells improves cartilage production: Cell combinations for cartilage production. [Plast Reconstr Surg. Aug 10. \[Epub ahead of print\]](#)
7. Dimitrellos, V. *et al.* (2003) Capillary electrophoresis and enzyme solid phase assay for examining the purity of a synthetic heparin proteoglycan-like conjugate and identifying binding to basic fibroblast growth factor. [Biomed Chromatogr. 17 \(1\): 42-7.](#)
8. Narcisi R *et al.* (2015) Long-term expansion, enhanced chondrogenic potential, and suppression of endochondral ossification of adult human MSCs via WNT signaling modulation. [Stem Cell Reports. 4 \(3\): 459-72.](#)
9. Lolli A *et al.* (2016) Silencing of anti-chondrogenic microRNA-221 in human mesenchymal stem cells promotes cartilage repair *in vivo*. [Stem Cells. Mar 1. \[Epub ahead of print\]](#)
10. de Kroon, L. M. G. *et al.* (2016) Activin and Nodal Are Not Suitable Alternatives to TGF for Chondrogenic Differentiation of Mesenchymal Stem Cells [Cartilage. Sep 7 \[Epub ahead of print\]](#)

11. Cleary, M.A. *et al.* (2016) Expression of CD105 on expanded mesenchymal stem cells does not predict their chondrogenic potential. [Osteoarthritis Cartilage. 24 \(5\): 868-72.](#)
12. Grotenhuis, N. *et al.* (2016) Biomaterials Influence Macrophage-Mesenchymal Stem Cell Interaction *In Vitro*. [Tissue Eng Part A. 22 \(17-18\): 1098-107.](#)
13. Rodrigues, A.I. *et al.* (2017) Calcium phosphates and silicon: exploring methods of incorporation. [Biomater Res. 21: 6.](#)
14. Le, B.Q. *et al.* (2015) High-Throughput Screening Assay for the Identification of Compounds Enhancing Collagenous Extracellular Matrix Production by ATDC5 Cells. [Tissue Eng Part C Methods. 21 \(7\): 726-36.](#)
15. Le, B.Q. *et al.* (2017) An Approach to In Vitro Manufacturing of Hypertrophic Cartilage Matrix for Bone Repair. [Bioengineering \(Basel\). 4 \(2\)Apr 20 \[Epub ahead of print\].](#)
16. Bach, F.C. *et al.* (2017) Link-N: The missing link towards intervertebral disc repair is species-specific. [PLoS One. 12 \(11\): e0187831.](#)
17. Pleumeekers, M.M. *et al.* (2018) Trophic effects of adipose-tissue-derived and bone-marrow-derived mesenchymal stem cells enhance cartilage generation by chondrocytes in co-culture. [PLoS One. 13 \(2\): e0190744.](#)

Storage

Prior to reconstitution store at -20°C. Following reconstitution store at -20°C.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee

Guaranteed for 3 months from the date of reconstitution or until the date of expiry, whichever comes first. Please see label for expiry date.

Health And Safety Information

Material Safety Datasheet documentation #10308 available at:
10308: <https://www.bio-rad-antibodies.com/uploads/MSDS/10308.pdf>

Regulatory

For research purposes only

North & South America Tel: +1 800 265 7376
Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

'M362351:200501'

Printed on 11 Aug 2020